Elizabeth joined the systematic review team at Mtech Access in 2021 after graduating from the University of Bristol with an MSci in Pharmacology (with year in industry). During a placement year, Elizabeth worked for AstraZeneca in the in vitro cardiovascular safety team. Here she developed in vitro cardiovascular models, using induced pluripotent stem cells, to assess drug cardiotoxicity. Her main project assessed the cardiovascular safety risks associated with novel protein degradation molecules. Her interest in systematic review stemmed from her extensive review on the use of induced pluripotent stem cell cardiomyocytes for the assessment of drug induced arrhythmias.
Elizabeth is involved in all areas of the systematic review process, contributing to activities that include developing study protocols, designing search strategies, publication screening, data extraction, and report writing across a range of therapeutic areas.